Lupin receives USFDA approval for Prednisolone Acetate Ophthalmic Suspension USP
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Revolutionary technology will further boost OneSource’s scientific services offerings
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Subscribe To Our Newsletter & Stay Updated